OVID
NASDAQ · Biotechnology
Ovid Therapeutics Inc
$2.84
-0.05 (-1.73%)
OVID News15 articles
Pfizer Stock Rises 7% as Non-COVID Drugs Offset Pandemic Revenue Decline
Pfizer shares rose 7% last week, driven by strong performance from Eliquis and other key drugs that offset declining COVID product sales.
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
UiPath Stock Trades Flat Despite Near-Float Volume; Buyback Provides Floor
UiPath (PATH) shares barely moved last week despite massive trading volume near the float, as the company's aggressive buyback program and elevated short interest create a tug-of-war.
Lloyds Shares Edge Higher as Buyback Provides Key Support Level
Lloyds shares gained 0.76% to 112.55p, trading near the average price of its latest 24-million-share buyback. The BoE's hawkish stance and proposed capital rule easing provide support, though housing weakness and motor finance uncertainty remain.
AMC Shares Jump as Summer Box Office Provides Key Test
AMC shares surged 9.5% Friday after a strong Memorial Day weekend, but the company's $3.96 billion debt and first-quarter loss remain key concerns.
Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines
A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.
Moderna Tops Q1 Revenue Forecast on International Covid Vaccine Sales, Hit by $900M Charge
Moderna's Q1 revenue surged to $389M on international Covid vaccine sales, but a $900M patent charge pushed net loss to $1.34B. Shares fell 2.7%.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Bitcoin Retreats as Iran Talks Stall, ETF Inflows Provide Support
Bitcoin fell back Sunday as geopolitical tensions resurfaced, though continued institutional demand via spot ETFs helped cushion the decline. Morgan Stanley's new Bitcoin fund marked a milestone for Wall Street adoption.
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
Apple Shares Slide Amid Tech Rout, India Production Hopes Provide Cushion
Apple shares declined nearly 2% to $255.76, trimming its market cap to approximately $4.05 trillion. The drop coincided with a broader tech sell-off driven by oil price spikes and the launch of new, more affordable Apple devices.
Bitcoin Retreats as Oil Spike Fuels Inflation Fears, ETF Inflows Provide Support
Bitcoin declined over 1% as escalating Middle East tensions drove oil prices higher, stoking inflation concerns. However, U.S. spot Bitcoin ETFs recorded significant inflows, highlighting conflicting market forces.
Nvidia Shares Dip as Market Awaits Earnings, Meta Deal Provides Support
Nvidia shares declined 0.7% to $186.69 in Thursday trading, giving back some of Wednesday's gains. The pullback comes ahead of next week's quarterly earnings report and amid broader semiconductor sector weakness.